Hudock Inc’s Charles River Laboratories CRL Stock Holding History

Hudock Inc’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-14	Closed	-$1K	–	700
2019 Q2	$1K	Hold	14	–	–	﹤0.01%	640
2019 Q1	$2K	Buy	+14	New	+$1.84K	﹤0.01%	579

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hudock Inc's CRL Position: Q3 2019 in Review

Hudock Inc sold out of Charles River Laboratories (CRL) in Q3 2019, closing a stake of 14 shares — an estimated $1K sold.

Hudock Inc first reported a position in CRL in Q1 2019 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

Hudock Inc reported no remaining Charles River Laboratories position as of Q3 2019 after selling out during the quarter.
Hudock Inc sold 14 Charles River Laboratories shares in Q3 2019, an estimated $1K.
Hudock Inc first reported a position in Charles River Laboratories in Q1 2019 and held it in 2 quarters.
Hudock Inc's Charles River Laboratories position peaked at $2K in Q1 2019.
396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Hudock Inc's 13F filing for Q3 2019, filed 31 Oct 2019.